Business Combinations (Tables)

9 Months Ended

Oct. 03, 2021

Business Acquisition [Line Items]

Schedule of Business Acquisitions, by Acquisition1 [Table Text Block]

The total purchase price for the acquisitions in fiscal year 2020 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows:

	Preliminary
	(In thousands)
Fair value of business combination:
Cash payments	$	437,661
Other liability	1,660
Working capital and other adjustments	(384)
Less: cash acquired	(26,840)
Total	$	412,097
Identifiable assets acquired and liabilities assumed:
Current assets	$	35,532
Property, plant and equipment	20,302
Other assets	18,114
Identifiable intangible assets:
Core technology	65,730
Trade names	5,580
Customer relationships	108,523
In-process research and development ("IPR&D")	10,700
Goodwill	221,960
Deferred taxes	(27,142)
Deferred revenue	(2,031)
Liabilities assumed	(45,171)
Total	$	412,097

Business Acquisition, Pro Forma Information [Table Text Block]

The following unaudited pro forma information presents the combined financial results for the Company and BioLegend as if the acquisition of BioLegend had been completed at the beginning of fiscal year 2020:

	Nine Months Ended		Fiscal Year Ended
	October 3, 2021		January 3, 2021
	(In millions, except per share data)
Pro Forma Statement of Operations Information:
Revenue	$	3,943	$	4,025
Income from continuing operations	797		552
Basic earnings per share:
Income from continuing operations	$	6.28	$	4.39
Diluted earnings per share:
Income from continuing operations	$	6.26	$	4.37